NCT01175395 - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Age-Related Macular DegenerationChoroidal Neovascularization

Interventions

DRUG

IBI-20089/Lucentis

Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.

Trial Locations (1)

60612

UIC Eye and Ear Infirmary, Chicago